Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. is a late-stage clinical specialty pharmaceutical company that develops and commercializes therapeutic products for rare and orphan diseases with limited or no approved treatments. The company's lead product, QRX003, is in clinical development for Netherton Syndrome (NS), a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Six clinical sites have been opened in the U.S., with international sites opening in the UK, Spain, France, and the Netherlands. QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies in Ireland, Austria, the Netherlands, and New Zealand. QRX003 is also being developed for Peeling Skin Syndrome, with the first subject treated in New Zealand, and the company is expanding this study to include up to an additional five pediatric subjects. Quoin Pharmaceuticals, Ltd. has a Research Agreement with Queensland University of Technology (QUT) in Australia, providing an option for a global license to QRX008 for scleroderma. The company also has a Research Agreement with The School of Pharmacy at University College Cork (UCC) for developing novel topical formulations of rapamycin (sirolimus) to treat rare and orphan diseases with limited or no approved therapies, including microcystic lymphatic malformations, venous malformations, and angiofibromas. The company has entered into 9 commercial partnerships for QRX003, covering 61 countries outside its core commercial territories of the U.S., Western Europe, and Japan. These partnership countries include Canada, Australia, New Zealand, the Middle East, China, Taiwan, Hong Kong, Singapore, Israel, Central and Eastern Europe, Turkey, and several countries in Latin America.